3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Dollar General disclosed that the FTC and various states filed a lawsuit against it on October 26, 2026, in federal court in Tennessee, alleging violations of the FTC Act, the Gramm-Leach-Bliley Act and state consumer protection laws. The FTC had also demanded significant monetary relief, and the company says it intends to defend the case but cannot assure a successful outcome, which could have a material adverse effect on its consolidated financial statements.
FTC and states filed suit October 26, 2026, in the U.S. District Court for the Middle District of Tennessee
Plaintiffs seek injunctive relief, monetary judgment and civil penalties; the filing does not state an amount
Draft complaint and draft settlement order were received September 23, 2026, after a Civil Investigative Demand dated January 30, 2026
Company says it will vigorously defend the matter and that defense could involve significant costs
The NYSE has begun proceedings to delist Eve Holding's public warrants, ticker EVEXW, and suspended trading in them because of an abnormally low selling price. The filing says the common stock, ticker EVEX, is not affected and continues to trade on the NYSE.
NYSE notified the company on October 21, 2026 and the company announced it publicly on October 22, 2026.
Warrants (EVEXW) are suspended from trading and the NYSE will apply to the SEC to delist them once procedures are complete.
Each warrant is exercisable for one share of common stock at $11.50 per share.
Common stock (EVEX) continues to trade on the NYSE, subject to the company's other listing requirements.
Nasdaq granted Zeo Energy Corp. an additional 180 calendar days to regain compliance with the $1.00 minimum bid price rule for its Class A common stock. The company's stock listing and trading on the Nasdaq Capital Market are not immediately affected, but the company says there is no assurance it will regain compliance.
Nasdaq letter dated October 22, 2026 extends the compliance deadline to April 19, 2027.
The original 180-day compliance period was set to end October 20, 2026, after Nasdaq's April 23, 2026 notice.
The minimum closing bid price required is $1.00 per share for Class A common stock.
The company intends to monitor its bid price and consider options to regain compliance.
Kinetik subsidiary EagleClaw Midstream Ventures agreed on October 23, 2026 to resolve a previously disclosed dispute with Energy Transfer over when an NGL purchase agreement expires. Under the settlement, both parties confirmed the agreement's final day of term is December 31, 2026. The filing notes that a related litigation over two Energy Transfer agreements, including this one, remains pending adjudication.
Settlement agreed October 23, 2026 between EagleClaw Midstream Ventures and Energy Transfer GC NGL Product Services
ECMV NGL purchase agreement final day of term confirmed as December 31, 2026
The agreement is one of two Energy Transfer agreements subject to previously disclosed litigation, which awaits adjudication
Cumberland Pharmaceuticals plans to submit a New Drug Application to the FDA for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy, seeking Traditional Approval based on its FIGHT DMD trial and natural history data. The FDA raised concerns that the proposed data package may not be sufficient to show substantial evidence of efficacy and requested additional analysis, and the company states there is no assurance the FDA will accept the filing or approve the drug.
The 12-month Phase 2 FIGHT DMD trial showed a statistically significant 5.4% absolute improvement in left ventricular ejection fraction (p=0.002) versus a control group.
The FDA suggested a Phase 3, randomized, placebo-controlled trial earlier in the review process, and expressed concerns about the sufficiency of the proposed data package at a pre-NDA meeting held this fall.
The FDA granted the company's request for rolling review of the NDA, allowing completed sections to be submitted before the full application.
The planned submission includes safety data from more than 1,400 subjects across approximately 30 clinical studies of ifetroban.
Azio AI Holdings told the SEC it believes it has regained compliance with Nasdaq's $2,500,000 minimum stockholders' equity requirement. The company cites a third-quarter 2026 business combination with Azio AI Corporation, warrant exercises, and stock issued under an equity purchase agreement, and it notes Nasdaq will keep monitoring compliance and may delist the stock if compliance is not shown at the next periodic report.
Nasdaq notified the company on April 29, 2026 that stockholders' equity was below the $2,500,000 minimum, based on its Form 10-K for 2025.
Nasdaq extended the deadline; the company had to file a public report demonstrating compliance on or before October 26, 2026.
In the third quarter of 2026 the company issued 2,460,351 common shares and 973,450 Series A Preferred shares in the Azio AI Corporation business combination, plus warrant exercises for 450,000 common shares and about 920,000 common shares
The company says actual results for the quarter ended September 30, 2026 may differ materially from preliminary unaudited figures.
Phathom Pharmaceuticals said the FDA has opened a public docket to seek comment on legal and regulatory questions tied to a challenge by generic filer BDR Pharmaceuticals over VOQUEZNA's exclusivity. The challenge follows FDA's June 6, 2025 decision that VOQUEZNA has 10 years of NCE exclusivity through May 3, 2032. If the challenge succeeds, exclusivity could be shortened and competing generic applications could be approved earlier than expected.
FDA docket No. FDA-2026-N-13038; comments due November 23, 2026
FDA's June 6, 2025 decision granted Phathom's Citizen Petition, recognizing NCE exclusivity through May 3, 2032
A second purported ANDA filer, Saba Ilac Sanayii Ve Ticaret AS, says it has a related case and plans to seek consolidation with BDR's case
Phathom believes the exclusivity remains in effect and will say so in its FDA comments and in court
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.